Nath Bio-genes (india) Ltd. · NSE:NATHBIOGEN
Nath Bio-genes (india) — Q4 FY2023 Earnings Presentation
27 slides from Nath Bio-genes (india)'s earnings presentation, Apr 22, 2023
Slide 1: Covering letter to stock exchanges on results presentation
22nd April 2023 The Manager-Listing The Manager-Listing BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Bandra (E) Mumbai-400001 Mumbai-400051 BSE Code-537291 NSE Code-NATHBIOGEN Dear Sir/Madam, Subject- Presentation on
Slide 2: One Seed, Many Lives: Q4 & FY23 Investor Presentation
One Seed, Many Lives Sustainable Value Creation Q4 & FY23 Investor Presentation
Slide 3: Disclaimer
Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual
Slide 4: Strategy for Sustainable Value Creation
Strategy for Sustainable Value Creation 1 TAILOR MADE 2 SUPERIOR 3 Strong R&D 4 INVESTMENT PRODUCTS PRODUCT Focus GRADE . PERFORMANCE BALANCE SHEET Customized products to High Yield and Strong Bio-tech integrated Zero Long Term Debt address key farmer Pest and Disease innovation requirements Resista
Slide 5: Competitive Positioning in a Tough Sector
Competitive Positioning in a Tough Sector Focus Area Winning Strategies Product Selection • Focus on Cotton, Vegetables, • Build a dream-product basket Fodder Bajra with superior and diversified products • Empower Stakeholders; Build long-term, loyal, symbiotic • Build an Un-paralleled Supply relati
Slide 6: What our Business Delivered in Last 5 Years
What our Business Delivered in Last 5 Years Average Selling Price (Rs/kg) is Revenue Growth (INR Cr) Increasing 1311 CAGR 10.4% 301 192 480 209 128 FY18 FY23 Field Crops Vegetables FY18 FY23 5
Slide 7: Tailor Made Products
Tailor Made Products 1 Understand key farmer requirements based on deep market research 2 Develop products to suit various agri climatic conditions 3 Focus on disease and pest resistance which automatically results in higher yield 4 Stringent multistage trials before commercial development 6
Slide 8: Our Success Stories
Our Success Stories — _
Slide 9: Sanket – #1
Sanket – #1 Market Need: • High level of resistance to sucking pest ü Only BT-Cotton hybrid in the Market • Yield losses ü High customer retention ü Recognized by Indian Ministry of Agriculture for its consistent performance through repeated All India What our R&D Produced: Coordinated Trials ü Expe
Slide 10: Testimonials: Sanket
Testimonials: “Sanket” Farmers on “Sanket” “खच# काम वाला कॉटन, क.ड़े क12ोल म4 और खचा# भी कम ” “क.ड़ा कम दवा कम और :यादा कपास ” 9
Slide 11: Super 27 - Deep-Rooting into Bajra
Super 27- Deep-Rooting into Bajra Market Need • High Yielding dual Purpose Hybrids • Crop window exploitation ü Product is seeing strong traction Our R&D efforts ü Addressable market of 3000 tons ü NBIL is expected to gain 50% market share in next two • High level of blast tolerance years • High bio
Slide 12: Testimonials: Super 27
Testimonials: “Super 27” Farmers on “Super 27” “इतने बड़े AसBटे वाला बiजारा मDने कभी दे खा नहFं था। AसBटा बहुत मजबत ू है और दाना भर भर के है ” “Mपछले साल मझ ु े सप ु र 27 के उSपाद भेजते वTत 100 Wपया XYत िTवंटल :यादा Aमले, इनके दान[का साइज और रं ग दे सी टाइप है ” “डबल धमाके वाला बाजरा है - साफ चारा और
Slide 13: Akhand - Best Performing
Akhand- Best Performing Market Need • Very deep red colour fruits with better shelf life • Virus resistant hybrid • Higher Yield ü Strong demand seen in the market - Zero inventory left ü Addressable market size - Rs 150cr Our R&D Efforts ü NBIL is expected to have 20% market share in next two years
Slide 14: Testimonials: Akhand
Testimonials: “Akhand” Farmers on “ Akhand ” “ठोस और मजबत ू फल, दरू भेजने के Aलए जबरदbत हD! नT ु सान भी कम हD” “लाल और टे bटF फल, एक सामान साइज हD” “एक जैसा फल और जबरदbत नफा होता हD” 13
Slide 15: Focussed on R&D
Focussed on R&D • Well Invested, DSIR • Produce Genetically Pure and Premium recognized R&D Innovation Quality Seeds Centers • Prioritise Disease and Pest resistance • Cold storage facilities, breeding warehouses, and conditioning godowns having a capacity of 20,000MT 02 03 • R&D Team of • Large and
Slide 16: Focussed on Shareholder Value Creation
Focussed on Shareholder Value Creation Growing Business Product Excellence Strong Positions in important crops Innovation and solution that drive productivity and create value for farmers Differentiated Customer Experience Margin Expansion Expanding market reach through new Growing EBITDA margins th
Slide 17: Q4 & FY23 Performance
Q4 & FY23 PERFORMANCE 16
Slide 18: Key Operating and Financial Highlights
Key Operating and Financial Highlights o Non-cotton, non-paddy portfolio contribution at 45%(up from 41% in FY22) to revenues; Revenue growth of 8.25% in FY23; o Cotton volumes increased by 16% and volumes of Paddy is maintained o Company is moving towards hybrid paddy sales which is driving value g
Slide 19: Segmental Revenue Contribution FY23
Segmental Revenue Contribution FY23 FY23 Revenue FY22 Revenue INR 3,012 Mn INR 2,784 Mn Cotton, 29% Others, 45% Cotton, 31% Others, 41% Paddy, 26% Paddy, 28% Cotton Paddy Othe rs Cotton Paddy Othe rs • Others include: Jowar, Bajra, Maize, Mustard, Wheat 18
Slide 20: Segment wise Operating Performance
Segment wise Operating Performance Products Metric FY23 YOY Growth FY22 Cotton Packets in lakhs 13.8 16.6% 11.90 Paddy Quintals 54,779 -7.4% 59,176 Other Crops (Bajra, Maize) Quintals 36,144 20.6% 29,963 Vegetables Quintals 2,555 -12.7% 2,929 19
Slide 21: Income Statement
Income Statement Particulars (INR Mn) Q4FY23 Q4FY22 FY23 FY22 Total Revenue 449 272 3,013 2,783 Gross Profit 283 197 1,668 1,544 Gross Margin (%) 62.9% 72.3% 55.3% 55.5% EBITDA 41 -212 489 373 EBITDA Margin (%) 9.2% -78.1% 16.2% 13.4% Depreciation 9 11 30 31 Finance Cost 15 25 101 106 PBT 18 -1128 3
Slide 22: Appendix
xs a 2” Lu a. a. og
Slide 23: Maintaining Profitability; Strong Balance Sheet
Maintaining Profitability; Strong Balance Sheet 888 Net Debt (INR Mn) Net Worth (INR Mn) 679 672 6133 659 5576 5420 5734 576 5076 4692 478 363 3033 207 1071 1213 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 -121 EBITDA Margin (%) PAT Margin (%) 22% 18% 18
Slide 24: Visionary Leadership; Attracting the Best Talent
Visionary Leadership; Attracting the Best Talent Mr. N Mr. Satish Nath Promoters are committed to sustainable Kagliwal Kagliwal MD growth and are working towards making Nath one Chairman of the best seeds companies globally. Leadership Team Research & Product Development Nath leadership team shares
Slide 25: Historical Income Statement
Historical Income Statement Nath Bio-Genes’ P&L Statement Particulars (INR Mn) FY23 FY22 FY21 FY20 Total Revenue 3,013 2,783 3,076 2,799 Gross Profit 1,668 1,544 1,715 1,536 Gross Margin (%) 55% 56% 56% 55% EBITDA 489 373 667 547 EBITDA Margin (%) 16% 13% 22% 20% Depreciation 30 31 28 14 Finance Cos
Slide 26: Historical Balance Sheet
Historical Balance Sheet Assets (INR Mn)FY FY23 FY22 FY21 FY20 Liabilities FY23 FY22 FY21 FY20 Fixed Assets 2,444 2,449 2,469 2,460 Share Capital 190 190 190 190 Financial Assets 51 51 53 52 Reserves & Surplus 5,544 5,230 5,943 5,386 Other Non-current Assets 225 218 134 15 Long-Term Borrowings 4 7 7
Slide 27: Thank You
Thank You CIN_NBIL_L01110MH1993PLC072842 For further information, please get in touch with: Sheetal Khanduja Deepika Sharma sheetal@GoIndiaadvisors.com deepika@GoIndiaadvisors.com M:+91 97693 64166 M:+918451029510 26
Nath Bio-Genes (India) — Q4 FY2023 Earnings Presentation on 6ix